Tocilizumab

證據等級: L5

預測適應症: 10 個

Tocilizumab: From Rheumatoid Arthritis to Ankylosing Spondylitis

One-Sentence Summary

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody originally developed for rheumatoid arthritis and juvenile idiopathic arthritis. TxGNN predicts it may also be effective for Ankylosing Spondylitis, but the supporting evidence — 9 clinical trials and 19 publications, including two dedicated Phase 3 trials — actually points toward a negative result rather than a positive signal.

Quick Overview

Item	Content
Original Indication	Rheumatoid Arthritis (established from literature evidence; no TFDA/Fimea license record available)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.99%
Evidence Level	L1
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as a High-severity data gap). Based on the literature evidence collected, tocilizumab is a humanized monoclonal antibody that blocks both membrane-bound and soluble IL-6 receptors, and it is established for use in rheumatoid arthritis (RA), systemic and polyarticular juvenile idiopathic arthritis, and giant cell arteritis — all conditions where IL-6 plays a central pathogenic role.

Rheumatoid arthritis and ankylosing spondylitis (AS) are both chronic inflammatory rheumatic diseases, which is likely why TxGNN's knowledge-graph model flagged AS as a high-scoring candidate (99.99%) — the two diseases share treatment classes (biologic DMARDs) and overlapping patient registries in the literature.

However, the mechanistic rationale is weaker than the score suggests: AS and axial spondyloarthritis are primarily driven by the IL-17/TNF axis, not IL-6. This is not a theoretical concern — it has already been tested directly. Two purpose-built Phase 3 randomized, placebo-controlled trials in AS patients (NCT01209689, NCT01209702) were conducted and both were terminated, having failed to demonstrate superiority over placebo (per the repurposing rationale, ASAS20 response was not significantly better than placebo). This is a case of direct clinical evidence returning a negative result, not a case of insufficient data.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01209689	Phase 3	Terminated	113	Pivotal placebo-controlled RCT in AS patients with inadequate response to prior anti-TNF therapy; trial terminated — negative pivotal result
NCT01209702	Phase 2/3	Terminated	306	Seamless Phase II/III RCT in NSAID-failure, TNF-naive AS patients; sister trial to NCT01209689, also terminated — negative result
NCT07477795	Phase 2	Not yet recruiting	52	Studies secukinumab, not tocilizumab, in Takayasu arteritis — drug mismatch, not directly applicable
NCT01965132	N/A	Recruiting	10,000	Korean multi-disease biologics/tsDMARD registry covering RA, AS and PsA; observational safety data only, no AS-specific efficacy signal
NCT02569736	N/A	Completed	60	Mechanistic study of tocilizumab's effect on T follicular helper cells — conducted in RA patients, not AS; indirect IL-6 biology reference only
NCT05670301	N/A	Recruiting	2,500	Observational cytokine-profiling study across systemic inflammatory diseases; not AS-specific interventional evidence
NCT07138898	Phase 2	Not yet recruiting	80	Perioperative immunosuppressant management around shoulder arthroplasty in rheumatology patients; not an AS efficacy trial
NCT02925338	N/A	Completed	1,431	Real-world registry of Inflectra (infliximab), not tocilizumab — drug mismatch
NCT05696106	N/A	Unknown	750,000	Large-scale registry study on risk of developing additional immune-mediated inflammatory diseases; not an AS treatment trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23765873	2014	RCT (BUILDER-1/2)	Annals of the Rheumatic Diseases	Randomized, placebo-controlled trials assessing short-term symptomatic efficacy of tocilizumab in AS — the primary clinical efficacy data source for this indication
26986130	2016	Systematic Review / Network Meta-analysis	Medicine	Comparative effectiveness of biologic regimens for AS across RCTs; provides comparative context for tocilizumab vs. other biologics
22452603	2012	Review	Inflammation & Allergy Drug Targets	Reviews the rationale and evidence for IL-6 antagonism specifically in AS
29290076	2018	Meta-analysis (Cohort)	Clinical Rheumatology	Quantifies serious infection risk with biologics (including tocilizumab) in AS/nr-axSpA RCTs
20959960	2011	Cohort/Review	Osteoporosis International	Systemic bone effects of biologic therapies in RA and AS
21803631	2011	Review	Joint Bone Spine	Reviews biologic agents for AS beyond TNFα antagonists, including IL-6 blockade
19822066	2009	Review	Clinical and Experimental Rheumatology	Compares biologics in RA vs. AS and notes differing pathogenesis and treatment response
33981717	2021	Case Report	Frontiers in Medicine	Two cases of successful tocilizumab treatment for AA amyloidosis complicating AS
32872025	2020	Case Report	Medicine	AS complicating Turner syndrome; literature review context
31852268	2020	Cohort	Expert Review of Clinical Immunology	Compares infection risk between non-biologics and biologics (including tocilizumab) in inflammatory arthritis

Finland Market Information

Tocilizumab currently has no market authorization in Finland (Fimea market status: Not Marketed, 0 licenses on record). No product/dosage-form data is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

Two purpose-built Phase 3 RCTs in AS (NCT01209689, NCT01209702) were directly tested and terminated without demonstrating efficacy over placebo, indicating IL-6 blockade is likely insufficient for a disease primarily driven by the IL-17/TNF axis. This is a high-quality negative finding, not a data gap — pursuing this indication further is not supported by current evidence.

To proceed, the following is needed:

TFDA/local package insert data (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action detail from DrugBank (DG002)
If repurposing tocilizumab remains a priority, consider redirecting resources toward candidates in this same Evidence Pack with materially stronger support — notably polyarticular JIA (rank 7, L1 evidence, decision stage S3, "Proceed with Guardrails," already an approved indication elsewhere) and RF-positive polyarticular JIA (rank 10, L2, "Proceed with Guardrails") — rather than Ankylosing Spondylitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.